Asia Pacific
Refine Search
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Photocure, a Norway-based bladder cancer-focused company, has announced that Jiangsu Yahong Meditech, the parent company of its partner Asieris Pharmaceuticals, has received marketing authorization for Hexvix (hexaminolevulinate) in China. 5 November 2024
Biotechnology
Japan’s Nxera Pharma – formerly known as Sosei – and Antiverse, a UK techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). 5 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung cancer (NSCLC ). 31 October 2024
Pharmaceutical
Japanese pharma major Takeda today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. 31 October 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
Takeda has release positive interim results from a Phase III-enabling proof-of-concept study for mezagitamab (TAK-079), a potential best-in-class anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN). 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Pharmaceutical
Corxel Pharmaceuticals and LENZ Therapeutics have reported encouraging topline results from a Phase III trial in China testing LENZ’s aceclidine-based eye drop, LNZ100. 29 October 2024
Pharmaceutical
Japanese drugmaker Shionogi saw its shares rise 2.3% to 2,173 yen today after it released positive research findings. 29 October 2024
Biotechnology
Yongyin-based biopharma company GC Biopharma has announced a partnership with Novelty Nobility for the joint development of a new treatment for geographic atrophy (GA). 28 October 2024
Pharmaceutical
Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP). 28 October 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Pharmaceutical
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Biotechnology
Japanese drugmaker Takeda has announced the exercise of its option to acquire Maverick Therapeutics, a private biopharma company pioneering conditionally active bispecific T-cell targeted immunotherapies. 9 March 2021
Biotechnology
Genomics-based drug discovery company Exelixis has announced an exclusive license agreement with WuXi Bio to support the continued expansion of its oncology biologics pipeline. 8 March 2021
Pharmaceutical
Japanese drug major Eisai says that its Hong Kong subsidiary Eisai (Hong Kong) Co has obtained approval for the in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. 2 March 2021
Biotechnology
Anglo-Swedish drugmaker AstraZeneca has been granted exclusive promotion rights for Junshi Biosciences’ toripalimab in mainland China for urothelial carcinoma and for all indications in non-core areas. 2 March 2021
Biotechnology
Swiss drug developer Idorsia has submitted a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for clazosentan, a fast-acting, selective endothelin A (ETA) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH). 1 March 2021
Biotechnology
Singapore’s Health Sciences Authority (HSA) has approved Piqray (alpelisib), an α-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor. 1 March 2021
Pharmaceutical
Agreement has been reached for Takeda to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of diabetes products in Japan to fellow Japanese firm Teijin Pharma. 26 February 2021
Pharmaceutical
Daiichi Sankyo has signed collaborations with European research groups to study the company’s valemetostat (DS-3201), a potential first-in-class EZH1/2 dual inhibitor, in B-cell malignancies starting with a Phase II study in patients with five subtypes of relapsed/refractory B-cell lymphoma. 25 February 2021
Biotechnology
Recent years have seen a growing number of Chinese biotechs doing their clinical studies outside China, reports The Pharma Letter’s local correspondent Wang Fangqing. 17 February 2021
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical announced today that it has refiled a patent infringement lawsuit with the Tokyo District Court, based on the substance patent owned by Chugai, regarding the generic drugs of an osteoporosis agent, active vitamin D3 derivative Edirol capsule 0.5 g / 0.75 g (eldecalcitol). 17 February 2021
Biotechnology
Takeda Pharmaceutical has announced new, late-breaking Phase III data from the TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK-620 (maribavir) which met its primary endpoint of superiority compared to conventional antiviral therapies. 15 February 2021
Biotechnology
South Korea's Celltrion Healthcare has announced that CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has confirmed neutralizing potency against emerging virus mutations and that the company has initiated development of a neutralizing antibody cocktail treatment with CT-P59. 11 February 2021
Biotechnology
The recent deal between Coherus BioSciences and Shanghai Junshi Biosciences for Junshi’s PD-1 inhibitor named Tuoyi (toripalimab) is the fifth such deal between the US or European Union companies and Chinese PD-1/L1 developers. 11 February 2021
Biotechnology
China’s Sinovac has reported positive Phase III data for its coronavirus vaccine, CoronaVac, with 50.65% overall efficacy after two weeks, following two doses. 8 February 2021
Biotechnology
Japanese drugmaker Daiichi Sankyo announced today that it recently entered into an outsourcing agreement with the local subsidiary of UK pharma majora AstraZeneca to manufacture the AstraZeneca/Oxford University-developed COVID-19 vaccine, AZD1222, in Japan. 5 February 2021
Biotechnology
The China National Medical Products Administration (NMPA) has granted conditional approval to Xospata (gilteritinib) for the treatment of adult patients who have relapsed (disease that has returned) or refractory (resistant to treatment) acute myeloid leukemia (AML) with a FLT3 mutation (FLT3mut+) detected by a fully validated test. 4 February 2021
Pharmaceutical
AstraZeneca’s Forxiga (dapagliflozin) has been approved in China to reduce the risk of cardiovascular (CV) death and hospitalisation for heart failure (hHF) in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF). 4 February 2021
Biotechnology
Japan’s Ono Pharmaceutical has entered into a license agreement with US clinical-stage oncology company Ribon Therapeutics for RBN-2397, Ribon’s PARP7 (Poly ADP-ribose polymerase 7) inhibitor in Phase I clinical development for the treatment of cancer. 2 February 2021
Pharmaceutical
US pharma major Eli Lilly has signed a license agreement with Asahi Kasei Pharma to acquire exclusive rights for AK1780 from the Japanese firm. 1 February 2021
Pharmaceutical
Ireland-headquartered drugmaker Mallinckrodt has won Japanese approval for its Cellex extracorporeal photopheresis (ECP) system. 29 January 2021
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze